Electrochemotherapy as an adjunct or alternative to other treatments for unresectable or in-transit melanoma

Mecker Moller, Slawomir Salwa, Declan M. Soden, Gerald C. O'Sullivan

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Treatment of recurrent or in-transit unresectable melanoma continues to be a major therapeutic challenge. Electrochemotherapy (ECT) is a therapeutic option for those patients whose lesions are not suitable for surgical resection and who have exhausted all other treatment modalities. ECT combines electroporation of tumor cells with the administration either of intravenous or intratumoral antineoplastic drugs, such as bleomycin or cisplatin. The cell membranes are thus rendered permeant to these impermeant hydrophilic drugs with a several hundred-fold increase in intracellular delivery and cytotoxicity. ECT is an effective treatment in the palliative management of unresectable recurrent disease with overall objective response rates of approximately 80-90%. ECT technology continues to evolve allowing application to deeper lesions. By combining ECT with tumor-specific immunostimulating approaches, such as perilesional IL-2, CpG oligonucleotides or prior immunogene therapy, there is a promise of both local and systemic control of this disease.

Original languageEnglish
Pages (from-to)1611-1630
Number of pages20
JournalExpert Review of Anticancer Therapy
Volume9
Issue number11
DOIs
StatePublished - Nov 1 2009
Externally publishedYes

Fingerprint

Electrochemotherapy
Melanoma
Therapeutics
Electroporation
Bleomycin
Palliative Care
Oligonucleotides
Intravenous Administration
Antineoplastic Agents
Cisplatin
Interleukin-2
Neoplasms
Cell Membrane
Technology
Pharmaceutical Preparations

Keywords

  • Electrochemotherapy
  • Electroporesis
  • In-transit
  • Melanoma
  • Recurrent
  • Treatment
  • Unresectable

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Oncology

Cite this

Electrochemotherapy as an adjunct or alternative to other treatments for unresectable or in-transit melanoma. / Moller, Mecker; Salwa, Slawomir; Soden, Declan M.; O'Sullivan, Gerald C.

In: Expert Review of Anticancer Therapy, Vol. 9, No. 11, 01.11.2009, p. 1611-1630.

Research output: Contribution to journalArticle

Moller, Mecker ; Salwa, Slawomir ; Soden, Declan M. ; O'Sullivan, Gerald C. / Electrochemotherapy as an adjunct or alternative to other treatments for unresectable or in-transit melanoma. In: Expert Review of Anticancer Therapy. 2009 ; Vol. 9, No. 11. pp. 1611-1630.
@article{80254e1a41da4838b0ac6c8ca7538a7e,
title = "Electrochemotherapy as an adjunct or alternative to other treatments for unresectable or in-transit melanoma",
abstract = "Treatment of recurrent or in-transit unresectable melanoma continues to be a major therapeutic challenge. Electrochemotherapy (ECT) is a therapeutic option for those patients whose lesions are not suitable for surgical resection and who have exhausted all other treatment modalities. ECT combines electroporation of tumor cells with the administration either of intravenous or intratumoral antineoplastic drugs, such as bleomycin or cisplatin. The cell membranes are thus rendered permeant to these impermeant hydrophilic drugs with a several hundred-fold increase in intracellular delivery and cytotoxicity. ECT is an effective treatment in the palliative management of unresectable recurrent disease with overall objective response rates of approximately 80-90{\%}. ECT technology continues to evolve allowing application to deeper lesions. By combining ECT with tumor-specific immunostimulating approaches, such as perilesional IL-2, CpG oligonucleotides or prior immunogene therapy, there is a promise of both local and systemic control of this disease.",
keywords = "Electrochemotherapy, Electroporesis, In-transit, Melanoma, Recurrent, Treatment, Unresectable",
author = "Mecker Moller and Slawomir Salwa and Soden, {Declan M.} and O'Sullivan, {Gerald C.}",
year = "2009",
month = "11",
day = "1",
doi = "10.1586/ERA.09.129",
language = "English",
volume = "9",
pages = "1611--1630",
journal = "Expert Review of Anticancer Therapy",
issn = "1473-7140",
publisher = "Expert Reviews Ltd.",
number = "11",

}

TY - JOUR

T1 - Electrochemotherapy as an adjunct or alternative to other treatments for unresectable or in-transit melanoma

AU - Moller, Mecker

AU - Salwa, Slawomir

AU - Soden, Declan M.

AU - O'Sullivan, Gerald C.

PY - 2009/11/1

Y1 - 2009/11/1

N2 - Treatment of recurrent or in-transit unresectable melanoma continues to be a major therapeutic challenge. Electrochemotherapy (ECT) is a therapeutic option for those patients whose lesions are not suitable for surgical resection and who have exhausted all other treatment modalities. ECT combines electroporation of tumor cells with the administration either of intravenous or intratumoral antineoplastic drugs, such as bleomycin or cisplatin. The cell membranes are thus rendered permeant to these impermeant hydrophilic drugs with a several hundred-fold increase in intracellular delivery and cytotoxicity. ECT is an effective treatment in the palliative management of unresectable recurrent disease with overall objective response rates of approximately 80-90%. ECT technology continues to evolve allowing application to deeper lesions. By combining ECT with tumor-specific immunostimulating approaches, such as perilesional IL-2, CpG oligonucleotides or prior immunogene therapy, there is a promise of both local and systemic control of this disease.

AB - Treatment of recurrent or in-transit unresectable melanoma continues to be a major therapeutic challenge. Electrochemotherapy (ECT) is a therapeutic option for those patients whose lesions are not suitable for surgical resection and who have exhausted all other treatment modalities. ECT combines electroporation of tumor cells with the administration either of intravenous or intratumoral antineoplastic drugs, such as bleomycin or cisplatin. The cell membranes are thus rendered permeant to these impermeant hydrophilic drugs with a several hundred-fold increase in intracellular delivery and cytotoxicity. ECT is an effective treatment in the palliative management of unresectable recurrent disease with overall objective response rates of approximately 80-90%. ECT technology continues to evolve allowing application to deeper lesions. By combining ECT with tumor-specific immunostimulating approaches, such as perilesional IL-2, CpG oligonucleotides or prior immunogene therapy, there is a promise of both local and systemic control of this disease.

KW - Electrochemotherapy

KW - Electroporesis

KW - In-transit

KW - Melanoma

KW - Recurrent

KW - Treatment

KW - Unresectable

UR - http://www.scopus.com/inward/record.url?scp=71949083522&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=71949083522&partnerID=8YFLogxK

U2 - 10.1586/ERA.09.129

DO - 10.1586/ERA.09.129

M3 - Article

C2 - 19895245

AN - SCOPUS:71949083522

VL - 9

SP - 1611

EP - 1630

JO - Expert Review of Anticancer Therapy

JF - Expert Review of Anticancer Therapy

SN - 1473-7140

IS - 11

ER -